CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
Amelie Franken(VIB-KU Leuven Center for Cancer Biology), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Jeroen Van Dessel(Universitair Ziekenhuis Leuven), Gino Philips(VIB-KU Leuven Center for Cancer Biology), Sabine Tejpar(KU Leuven), Cedric Van Aerde(Universitair Ziekenhuis Leuven), Katy Vandereyken(Allen Institute for Brain Science), Thierry Voet(Wellcome Sanger Institute), Esther Hauben(Universitair Ziekenhuis Leuven), Valentina Pomella(Universitair Ziekenhuis Leuven), Michel Bila(Universitair Ziekenhuis Leuven), Sara Verbandt(Universitair Ziekenhuis Leuven), Junbin Qian(Women's Hospital, School of Medicine, Zhejiang University), Orian Bricard(VIB-KU Leuven Center for Cancer Biology), Vincent Vander Poorten(KU Leuven), Vincent Vandecaveye(KU Leuven), Bram Boeckx(VIB-KU Leuven Center for Cancer Biology), Thomas Van Brussel(VIB-KU Leuven Center for Cancer Biology), Sarah Geurs(Vlaams Instituut voor Biotechnologie), Sam Kint(KU Leuven), Sigrid Hatse(Rega Institute for Medical Research), Sebastiaan Vanuytven(KU Leuven), Aurelie Mechels(VIB-KU Leuven Center for Cancer Biology), Paul M. Clément(Universitair Ziekenhuis Leuven), Rogier Schepers(VIB-KU Leuven Center for Cancer Biology), Jieyi Xiong(Chinese Academy of Sciences)
Cited by 108
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Methods and applications for single-cell and spatial multi-omics
|Nature Reviews Genetics|2023|1.1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573